There was a significant increase in CD8+ and CD68 + T-cell infiltration from baseline tumor samples to day 5 of treatment (CD8: Wilcoxon signed-rank test V = 57, P = 0.032, n = 11, Fig. 6A, B, CD68: Wilcoxon signed-rank test V = 56, P = 0.042, n = 11), but not of CD4+ cells (Supplementary Fig. 3A). The gene discussed is CD68; the disease is neoplasm.